Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 10/20 | 0.62 |
| ▸ | CD40 | P25942 | 1/20 | 0.49 |
| ▸ | CD40LG | P29965 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.48 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.48 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PHLPP2 | Q6ZVD8 | 3/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913411 | 0.95 | ENPP2 (0.68) | ENPP2CD40CD40LGPRMT1PRMT3 | |
| SCHEMBL12757652 | 0.91 | ENPP2 (0.61) | ENPP2CD40CD40LGPRMT1PRMT3 | |
| SCHEMBL19234809 | 0.91 | ENPP2 (0.67) | ENPP2CD40CD40LGPRMT1PRMT3 | |
| SCHEMBL12757650 | 0.89 | ENPP2 (0.60) | ENPP2CD40CD40LGPRMT1PRMT3 | |
| SCHEMBL14001677 | 0.89 | ENPP2 (0.51) | ENPP2CD40CD40LGPRMT1PRMT3 | |
| SCHEMBL15386690 | 0.88 | ENPP2 (0.63) | ENPP2CD40CD40LGPRMT1PRMT3 | |
| SCHEMBL14773721 | 0.88 | ENPP2 (0.63) | ENPP2CD40CD40LGPRMT1PRMT3 | |
| SCHEMBL14773624 | 0.88 | ENPP2 (0.60) | ENPP2CD40CD40LGPRMT1PRMT3 | |
| SCHEMBL19958192 | 0.87 | ENPP2 (0.75) | ENPP2CD40CD40LGPRMT1PRMT3 | |
| SCHEMBL12757648 | 0.87 | ENPP2 (0.68) | ENPP2CD40CD40LGPRMT1PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7445822-B2 | Azo compounds and dye-type polarizing films or plates containing the same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-11-04 | — | — | US | disclosed |
| US-20080094549-A1 | Azo Compounds And Dye-Type Polarizing Films Or Plates Containing The Same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080094549-A1 | Azo Compounds And Dye-Type Polarizing Films Or Plates Containing The Same | CRY1, SCO2, SPR | ENPP2 1986/4885CD40 3865/4885CD40LG 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.